Literature DB >> 28732565

Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy.

Athanasios D Anastasilakis1, Dimitrios Koulaxis2, Nikoleta Kefala3, Stergios A Polyzos4, Jagriti Upadhyay5, Eirini Pagkalidou6, Fotios Economou2, Chrysostomos D Anastasilakis7, Christos S Mantzoros5.   

Abstract

BACKGROUND: Several myokines are produced by cardiac muscle. We investigated changes in myokine levels at the time of acute myocardial infarction (MI) and following reperfusion in relation to controls.
METHODS: Patients with MI (MI Group, n=31) treated with percutaneous coronary intervention (PCI) were compared to patients with stable coronary artery disease (CAD) subjected to scheduled PCI (CAD Group, n=40) and controls with symptoms mimicking CAD without stenosis in angiography (Control Group, n=43). The number and degree of stenosis were recorded. Irisin, follistatin, follistatin-like 3, activin A and B, ALT, AST, CK and CK-MB were measured at baseline and 6 or 24h after the intervention.
RESULTS: MI and CAD patients had lower irisin than controls (p<0.001). MI patients had higher follistatin, activin A, CK, CK-MB and AST than CAD patients and controls (all p≤0.001). None of the myokines changed following reperfusion. Circulating irisin was associated with the degree of stenosis in all patients (p=0.05). Irisin was not inferior to CK-MB in predicting MI while folistatin and activin A could discriminate MI from CAD patients with similar to CK-MB accuracy. None of these myokines was altered following PCI in contrast to CK-MB.
CONCLUSIONS: Irisin levels are lower in MI and CAD implying that their production may depend on myocadial blood supply. Follistatin and activin A are higher in MI than in CAD suggesting increased release due to myocardial necrosis. They can predict MI with accuracy similar to CK-MB and their role in the diagnosis of MI remains to be confirmed by prospective large clinical studies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activin; Follistatin; Irisin; Myocardial infarction; Percutaneous coronary intervention

Mesh:

Substances:

Year:  2017        PMID: 28732565     DOI: 10.1016/j.metabol.2017.05.002

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  20 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

2.  Irisin promotes cardiac progenitor cell-induced myocardial repair and functional improvement in infarcted heart.

Authors:  Yu Tina Zhao; Jianguo Wang; Naohiro Yano; Ling X Zhang; Hao Wang; Shouyan Zhang; Gangjian Qin; Patrycja M Dubielecka; Shougang Zhuang; Paul Y Liu; Y Eugene Chin; Ting C Zhao
Journal:  J Cell Physiol       Date:  2018-09-01       Impact factor: 6.384

Review 3.  Irisin Regulates Cardiac Responses to Exercise in Health and Diseases: a Narrative Review.

Authors:  Baishu Zhu; Bin Wang; Chen Zhao; Yuanxin Wang; Yalan Zhou; Junjie Lin; Renqing Zhao
Journal:  J Cardiovasc Transl Res       Date:  2022-08-29       Impact factor: 3.216

Review 4.  Irisin is an Effector Molecule in Exercise Rehabilitation Following Myocardial Infarction (Review).

Authors:  Shuguang Qin; Zhenjun Tian; Maxime Boidin; Benjamin J R Buckley; Dick H J Thijssen; Gregory Y H Lip
Journal:  Front Physiol       Date:  2022-06-29       Impact factor: 4.755

5.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

Review 6.  Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Chrysoula Boutari; Nikolaos Perakakis; Christos Socrates Mantzoros
Journal:  Endocrinol Metab (Seoul)       Date:  2018-03

Review 7.  The Role of Cardiokines in Heart Diseases: Beneficial or Detrimental?

Authors:  Ye-Shun Wu; Bin Zhu; Ai-Lin Luo; Ling Yang; Chun Yang
Journal:  Biomed Res Int       Date:  2018-03-18       Impact factor: 3.411

8.  Decreased level of irisin, a skeletal muscle cell-derived myokine, is associated with post-stroke depression in the ischemic stroke population.

Authors:  Wen-Jun Tu; Han-Cheng Qiu; Qiang Liu; Xuemei Li; Ji-Zong Zhao; Xianwei Zeng
Journal:  J Neuroinflammation       Date:  2018-05-02       Impact factor: 8.322

9.  Increased activin A levels in prediabetes and association with carotid intima-media thickness: a cross-sectional analysis from I-Lan Longitudinal Aging Study.

Authors:  Chin-Sung Kuo; Ya-Wen Lu; Chien-Yi Hsu; Chun-Chin Chang; Ruey-Hsing Chou; Li-Kuo Liu; Liang-Kung Chen; Po-Hsun Huang; Jaw-Wen Chen; Shing-Jong Lin
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

Review 10.  The Controversial Role of Irisin in Clinical Management of Coronary Heart Disease.

Authors:  Wen-Lu Ou-Yang; Bei Guo; Feng Xu; Xiao Lin; Fu-Xing-Zi Li; Su-Kang Shan; Feng Wu; Yi Wang; Ming-Hui Zheng; Qiu-Shuang Xu; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-01       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.